Stock Ticker

  • Loading stock data...

Novavax, Inc (NASDAQ:NVAX) Chooses Australia For Its COVID-19 Clinical Trials

The deadly COVID-19 pandemic continues to affect lives globally, with many people hardly affording to pay their house rent. It is frustrating that until no scientific cure to help handle the condition has been established yet. However, any good efforts mean a lot to frustrated people globally. There are reports about another candidate that is being considered a potential cure, and the clinical trials are currently underway. Novavax, Inc (NASDAQ:NVAX) says it has started its clinical trials as it continues inspiring hope among people globally.

This business guru has settled for Australia in carrying out its clinical trials and has succeeded in injecting several volunteers.

This late-stage biotech company has remained rather competitive as it continues carrying out its operations in Maryland; it remains the glimmer of hope for people globally. However, it is important to outline that so far, the business guru doesn’t have a single approved vaccine or product.

Novavax has revealed its plans on the way forward. It outlines that it has already decided on the way it will be going about its operations. It intends to settle for about 131 volunteers who will be injected with its vaccines.

It has also progressed to outline the different ages of the persons involved in the trials. According to it, the volunteers are aged between 18 to 59 years. As mentioned earlier, the tests take place in Australia in some two separate sites. It will be seeking to strike a proper determination of the general effectiveness as well as the safety level of the potential vaccine.

The business mogul has already named the vaccine NVX‑CoV2373, and it falls under its Phase I portion of the clinical trials. Novavax says that it has already decided on how it will be going about the tests. It plans to inject doses of 5 and 25 micrograms in the volunteers, and it looks forward to the most outstanding results.

The company hopes that it will be able to deploy the vaccine towards the end of this year if mattes turn out well.

Published by Duncan Oleinic

Duncan Oleinic is from New Yourk. After graduating with a degree in physics, he began his career as an analyst in a broking firm. Through this experience he was able to advance to the role of correspondent for a U.S based financial news provider, where he worked from 2001 to 2007. He subsequently joined a merchant banking firm as a financial analyst focused on valuing unlisted companies in the sub-continent. Over the course of his two years here, he performed valuations of several media companies which were later acquired by peers.

  • Recent Stories

    SignUp Now For Our Featured Newsletter

    Sign Up To Get Our Latest Stocks Alerts